Advancing Operational Excellence: Optimizing ESR1 Testing in Oncology Care

Join us for an in-depth exploration of endocrine therapy resistance in HR+, HER2- advanced breast cancer, with a focus on ESR1 mutations and their impact on treatment decisions.

This session will cover essential insights to guide clinical practice:

• Types of endocrine therapy resistance and the role of ESR1 mutations

• Testing guidelines and clinical implementation of ESR1 mutation testing

• Available therapies targeting ESR1 mutations and best practices for patient care

Speakers:
Julia Lea Ziegengeist, PharmD, BCOP | Atrium Health
Heather N. Moore, PharmD, BCOP, CPP | Duke University Hospital

If you have any questions or would like to request the meeting invite, contact Jonathan Rivera.